biofrontera-us.com (BFRI) Company Long-Term Loans and Borrowings

Biofrontera - graphic logo of issuer BFRI

Biofrontera Inc. (BFRI) management is currently aggressively scaling the sales of dermatological products in the US, leveraging shareholder confidence. The price action available for analysis on GURU.Markets, where the individual debt metric stands at 0.01, is subject to the influence of logistical disruptions and sanctions restricting system exports. The business is based on innovations in PDT therapy, offering benchmark treatment for skin precancer using Ameluz and BF-RhodoLED lamps.

BFRI Biofrontera, Inc.: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Analytical breakdowns for Biofrontera (BFRI)

- price and consensus price forecast:
Stock Price Biofrontera, Inc.|BFRI - Price Target Chart
- market capitalization data:
Market Value Biofrontera|BFRI - Total Company Value
- book capitalization data:
Accounting Value per Share Biofrontera|BFRI - Book Capitalization|Market Capitalization to Book Value Ratio biofrontera-us.com|BFRI - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Biofrontera Inc.|BFRI - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Biofrontera, Inc.|BFRI - Company Debts|Debts to Book Capitalization Biofrontera|BFRI - Company Long-Term Debts|Short-Term Debt Volume Biofrontera
Summary company analytics:BFRI (Biofrontera Inc.)
Manufactured products of Biofrontera Inc.

The specifics of the Biofrontera Inc. (BFRI) dermatological business are coupled with limited capital and pressure from generics. Long-term debt aggregates all credit obligations with maturities exceeding one year, measuring the overall debt load. A reduction in this volume confirms the sustainability of the financial strategy and solvency. An increase in borrowings amid litigation risks signals a liquidity shortage. This chart of the issuer's long-term liabilities clearly captures the actual progress of deleveraging.

Competing companies

krystalbio.com - Company Long-Term Debts|Company Long-Term Debt Apogee Therapeutics, Inc. (APGE)|ARQT: Company Long-Term Loans and Borrowings|VCEL (Vericel Corp.) - Company Long-Term Debt|Oruka Pharma (ORKA) - Company Long-Term Liabilities|SMTI (Sanara MedTech, Inc.) - Company Long-Term Debts|Company Long-Term Debts DBV Technologies SA (DBVT)|Solesence Inc (SLSN) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings DERM (journeymedicalcorp.com)|Company Long-Term Debt FBRX|Empro Corporation - Long-Term Debt Volume|Sol-Gel Technologies - Company Long-Term Debt|AXIL - Company Long-Term Debts|Medicus Pharma - Company Long-Term Debts|VRCA (Verrica Pharmaceuticals Inc.) - Long-Term Debt Volume|Company Long-Term Debt Hoth Therapeutics Inc. (HOTH)|Company Long-Term Indebtedness VYNE Therapeutics Inc|Company Long-Term Debts Sonoma Pharmaceuticals (SNOA)|Company Long-Term Debt quoinpharma.com (QNRX)|Company Long-Term Debts AZTR|Dermata Therapeutics Inc - Long-Term Debt Volume|ELAB (Elevai Skincare) - Company Long-Term Debt|RVNC - Long-Term Debt